Percutaneous Electrical Nerve Field Stimulator System (IB-Stim) for Functional Abdominal Pain Disorders
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governs medical necessity and coverage for the IB-Stim percutaneous electrical nerve field stimulator for pediatric patients (ages 11-18) with Rome IV-defined functional gastrointestinal disorders, for Medicare Advantage and Commercial products of Blue Cross Blue Shield - Rhode Island.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Medical necessity criteria
Covered when ALL of the following are met:
Eligibility criteria for medical necessity (Medicare Advantage and Commercial)
- Age: Patient is between 11 and 18 years of age.
- Diagnosis: Diagnosed with a ROME IV-defined functional gastrointestinal disorder (includes functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, or abdominal migraine).
- Rule-out of organic disease: Organic gastrointestinal disease has been ruled out.
- Symptom duration: Gastrointestinal symptoms have been present for at least 9 months.
Prior therapies
- Medication category A: Acid suppression (H2-blockers or proton pump inhibitors).
- Medication category B: Antispasmodics or motility medications (examples: hyoscyamine, dicyclomine, erythromycin, linaclotide, prucalopride).
- Medication category C: Neuromodulators (examples: amitriptyline, nortriptyline, gabapentin, periactin, aprepitant).
- Contraindications / exclusions: No history of cardiac pacemaker, hemophilia, or psoriasis vulgaris.
Individuals with a history of a cardiac pacemaker, hemophilia, or psoriasis vulgaris are excluded from eligibility for IB-Stim per the medical necessity criteria.
All other uses of the percutaneous electrical nerve field stimulator system (IB-Stim) that do not meet the specified medical necessity criteria are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.
Billing and Coding
| 0720T | Percutaneous electrical nerve field stimulation, cranial nerves, without implantation |
Provider Requirements and Operational Notes
Prior authorization required for IB-Stim (CPT 0720T)
Prior authorization is required for IB-Stim (CPT 0720T) for Medicare Advantage Plans; prior authorization is recommended for Commercial Products.
- Procedure code: 0720T
Required prior medication trials (3 classes)
Medical necessity requires documented failure of at least one medication from each of three classes, in addition to diet modification, before IB-Stim is considered.
- Acid suppression (H2-blockers or PPIs)
- Antispasmodics or motility medications (hyoscyamine, dicyclomine, erythromycin/linaclotide, prucalopride)
- Neuromodulators (amitriptyline, nortriptyline, gabapentin, periactin, aprepitant)
Verify benefits and obtain prior authorization
Verify member benefits and obtain prior authorization as required for Medicare Advantage (recommended for Commercial); document eligibility per the member's Benefit Booklet or Evidence of Coverage.
- Confirm coverage details in the Benefit Booklet, Evidence of Coverage, or Subscriber Agreement
- Obtain prior authorization for Medicare Advantage; consider prior authorization for Commercial
Coverage contingent on meeting all listed criteria
Coverage is contingent on meeting all listed medical necessity criteria; use that does not meet these criteria is not covered for Medicare Advantage and not medically necessary for Commercial Products.
- All criteria must be met: age 11–18, ROME IV diagnosis, organic GI disease ruled out, ≥9 months of symptoms, required medication trials plus diet modification, and no history of cardiac pacemaker, hemophilia, or psoriasis vulgaris
- If any criterion is not met, the IB-Stim is not covered/not medically necessary
Background and Clinical Context
Pediatric abdominal pain–related functional gastrointestinal disorders (FAPDs) encompass conditions such as functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, and abdominal migraine. The IB‑Stim is a percutaneous electrical nerve field stimulator intended for children and adolescents aged 11–18 years diagnosed with a ROME IV–defined functional GI disorder when organic disease has been ruled out, symptoms have persisted for at least 9 months, and required medication and diet trials have failed per the policy criteria.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.